Praxis Precision Medicines, Inc. (PRAX)

Market Cap	1.07B
Revenue (ttm)	7.77M
Net Income (ttm)	-251.01M
Shares Out	21.05M
EPS (ttm)	-12.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	286,984
Open	54.62
Previous Close	54.38
Day's Range	50.76 - 55.79
52-Week Range	26.70 - 91.83
Beta	2.64
Analysts	Strong Buy
Price Target	93.30 (+83.01%)
Earnings Date	Nov 5, 2025

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: PRAX
• Website: https://praxismedicines.com

Financial Performance

In 2024, PRAX's revenue was $8.55 million, an increase of 249.53% compared to the previous year's $2.45 million. Losses were -$182.82 million, 48.3% more than in 2023.

Analyst Summary

According to 10 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price target is $93.3, which is an increase of 83.01% from the latest price.

Price Target

$93.3

(83.01% upside)

Analyst Consensus: Strong Buy